Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin

Inclusion Criteria: * Healthy * Postmenopausal * Body weight \> 50 kg * Body mass index (BMI) between 19 and 30 * The subject is willing and able to give a signed and dated written informed consent prior to admission to the study * The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions. Exclusion Criteria: * Subjects with known morphea or sclerodermia * Subjects with a history of myocardial infarction. * Subjects with a history of renal/or hepatic disease unless the disease has been successfully treated and is no longer active; subjects with any evidence of renal/ or hepatic impairment on the screening physical and laboratory examination. * Subjects with history of hypertension or systolic blood pressure * Subjects with history of diabetes * History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening. * History of use of tobacco- or nicotine-containing products within 6 months of screening, or a positive urine cotinine indicative of smoking at screening. * Positive urine drug screen including alcohol (or alcohol breath test) at screening. * Positive for HIV, hepatitis B virus or hepatitis C virus. * Donation of blood in excess of 500 mL within 56 days prior to dosing * History of sensitivity or contraindications to any of the study medications (i.e., relacatib, paracetamol, ibuprofen or atorvastatin) or components thereof. * Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication. * Subjects whom are judged by the investigator to be at risk for acute angle closure glaucoma.